Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have earned an average recommendation of “Reduce” from the nine research firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $1.4714.

A number of equities research analysts have commented on the stock. Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Robert W. Baird set a $1.10 target price on Definitive Healthcare in a report on Friday, May 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $1.00 price target on shares of Definitive Healthcare in a research note on Wednesday, August 12th. Finally, Bank of America reaffirmed an “underperform” rating and set a $0.70 price target on shares of Definitive Healthcare in a report on Monday, June 29th.

Definitive Healthcare Stock Performance

Shares of Definitive Healthcare stock opened at $0.81 on Friday. Definitive Healthcare has a one year low of $0.61 and a one year high of $4.35. The company has a market cap of $86.93 million, a PE ratio of -0.51, a P/E/G ratio of 9.75 and a beta of 1.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.86 and a current ratio of 1.86. The business has a 50-day simple moving average of $0.74 and a 200-day simple moving average of $0.96.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. The firm had revenue of $55.20 million for the quarter, compared to analyst estimates of $55.47 million. Definitive Healthcare had a negative net margin of 72.28% and a positive return on equity of 3.55%. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. On average, equities research analysts forecast that Definitive Healthcare will post 0.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC boosted its holdings in Definitive Healthcare by 56.7% in the first quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock valued at $1,706,000 after purchasing an additional 213,562 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Definitive Healthcare by 564.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after buying an additional 7,404,363 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Definitive Healthcare by 166.0% during the 1st quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock worth $304,000 after buying an additional 65,597 shares during the last quarter. Creative Planning boosted its holdings in shares of Definitive Healthcare by 41.7% in the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after buying an additional 8,428 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Definitive Healthcare in the 2nd quarter valued at $4,247,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.